×
ADVERTISEMENT

AUGUST 21, 2024

FDA Approves Neoadjuvant/Adjuvant Imfinzi for Resectable NSCLC


Originally published by our sister publication Clinical Oncology News

The FDA has approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥4 cm and/or node-positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.